NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
Alexandra Frazao1, Louise Rethacker1, Meriem Messaoudene1,2
1INSERMU1160, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France.
Abstract:
The antitumor functions of NK cells are regulated by the integration of positive and negative signals triggered by numerous membrane receptors present on the NK cells themselves. Among the main activating receptors, NKG2D binds several stress-induced molecules on tumor targets. Engagement of NKG2D by its ligands (NKG2D-Ls) induces NK cell activation leading to production of cytokines and target cell lysis. These effects have therapeutic potential as NKG2D-Ls are widely expressed by solid tumors, whereas their expression in healthy cells is limited. Here, we describe the genetic and environmental factors regulating the NKG2D/NKG2D-L pathway in tumors. NKG2D-L expression is linked to cellular stress and cell proliferation, and has been associated with oncogenic mutations. Tumors have been found to alter their to NKG2D-L expression as they progress, which interferes with the antitumor function of the pathway. Nevertheless, this pathway could be advantageously exploited for cancer therapy. Various cancer treatments, including chemotherapy and targeted therapies, indirectly interfere with the cellular and soluble forms of NKG2D-Ls. In addition, NKG2D introduced into chimeric antigen receptors in T- and NK cells is a promising tumor immunotherapy approach.
Insights
Natural killer (NK) cells fight tumors via the NKG2D receptor pathway. Tumors can evade this, but targeting NKG2D-ligands offers promising cancer immunotherapy strategies.
Area of Science:
- Immunology
- Cancer Biology
- Molecular Oncology
Background:
- Natural killer (NK) cells possess antitumor functions regulated by membrane receptors.
- The NKG2D receptor on NK cells binds stress-induced molecules (NKG2D-ligands) on tumor cells, activating NK cells for cytokine production and target lysis.
- NKG2D-ligands are highly expressed on solid tumors, making the NKG2D/NKG2D-ligand pathway a potential therapeutic target.
Purpose of the Study:
- To investigate the genetic and environmental factors influencing the NKG2D/NKG2D-ligand pathway in tumors.
- To explore the therapeutic potential of exploiting the NKG2D/NKG2D-ligand pathway for cancer treatment.
Main Methods:
- Review of literature on NKG2D/NKG2D-ligand regulation in tumors.
- Analysis of factors affecting NKG2D-ligand expression in tumor progression.
- Examination of how cancer treatments impact the NKG2D/NKG2D-ligand pathway.
- Evaluation of NKG2D-based chimeric antigen receptor therapies.
Main Results:
- NKG2D-ligand expression is associated with cellular stress, proliferation, and oncogenic mutations.
- Tumor progression can alter NKG2D-ligand expression, potentially hindering NK cell-mediated antitumor activity.
- Conventional cancer therapies can indirectly affect NKG2D-ligand levels.
- NKG2D-based chimeric antigen receptors represent a novel immunotherapy approach.
Conclusions:
- The NKG2D/NKG2D-ligand pathway is a critical component of NK cell antitumor immunity, subject to regulation by tumor-specific factors.
- Despite tumor-induced interference, this pathway holds significant therapeutic promise.
- Targeting NKG2D-ligands or utilizing NKG2D-based immunotherapies could enhance cancer treatment efficacy.
Related Concept Videos
02:56Treatment Resistant Cancers
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
02:40Ligand Binding Sites
02:51Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
00:49Ligand Binding and Linkage
00:49Ligand Binding and Linkage